ev-103 cohort k: enfortumab vedotin /- pembro in untreated cis-ineligible patients with muc
Published 2 years ago • 531 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
1:24
ev-103 cohort h: neoadjuvant enfortumab vedotin monotherapy in cisplatin-ineligible mibc
-
2:09
ev-103: neoadjuvant enfortumab vedotin in cis-ineligible mibc
-
2:43
ev-103: ev with pembrolizumab in cisplatin-ineligible urothelial carcinoma
-
13:47
ev-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma
-
1:21
enfortumab vedotin and pembrolizumab vs platinum-based combination therapies for patients with muc
-
2:10
initial ev-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
-
1:08
the future of enfortumab vedotin in different stages bladder cancer
-
0:45
prof. siefker-radtke on the ev-103 trial in bladder cancer
-
11:29
enfortumab vedotin plus pembrolizumab: results of the ev-302 trial with thomas powles, md
-
2:06:04
uromet 3.1
-
18:36
breakthrough in bladder cancer: fda approval - enfortumab vedotin pelbrolizumab with dr.tom powles
-
3:07
enfortumab vedotin in urothelial cancer
-
0:49
evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
-
0:30
enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
-
2:55
ev-103: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carc...
-
1:59
enfortumab vedotin as monotherapy in heavily pretreated mcrpc
-
2:58
ev-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
-
0:35
ev-302: 1l enfortumab vedotin in combination with pembrolizumab
-
6:02
ev-103: ev pembrolizumab as a promising first-line option for urothelial carcinoma
-
3:24
enfortumab vedotin as treatment for urothelial carcinomas
-
4:15
ev-201: enfortumab an option for cisplatin-ineligible advanced uc | arjun balar
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer